HS research update (2026-08-15): What’s new on PubMed?

Canonical URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-08-15/
Markdown URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-08-15.md
Plain text URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-08-15.txt
Language: en
Category: Research
Published: 2026-08-15
Last updated: 2026-08-15
Last editorially reviewed: 2026-08-15
Next scheduled review: 2027-08-15

Author: Dr. rer. nat. Dennis Alexander Kwiatkowski (Biochemist, Scientific Writer and Pharma Expert)
Scientific editor: Dr. rer. nat. Dennis Alexander Kwiatkowski
Reviewer qualifications: Biochemist, Scientific Writer and Pharma Expert
Review scope: Scientific literature, clinical guidelines, sources, and editorial clarity
Clinical reviewer: No independent clinical review
Tags: Acne Inversa, Hidradenitis Suppurativa, HS, Research, hidradenitis suppurativa, acne inversa, research update, biologics, comorbidities, diagnostic delay, jak inhibitor, pain, quality of life, surgery, wound care
A patient-friendly overview of new PubMed publications on hidradenitis suppurativa (acne inversa) — with sources, clear limitations, and no medical advice.

Medical disclaimer: This website is for general educational information only and does not replace medical advice, diagnosis, or treatment. Please speak with qualified medical professionals about symptoms or treatment decisions.

Article

Publication overview

This update includes 35 PubMed publications with abstracts from the monitoring window 2026-08-01 to 2026-08-15. The most common themes are comorbidities, biologics, pain, surgery, wound care.

- Compared with the previous update: not automatically assessed.
- No guideline/NEJM/Lancet-style high-impact matches with abstracts in this window.
- This is a research overview, not a guideline update or medical recommendation.

Top highlights

The most useful signal this round is not a single treatment instruction. It is what researchers are looking at more closely: wound healing after procedures, possible new anti-inflammatory approaches, care quality, and comorbidities.

- Does Alexithymia Affect Patients with Hidradenitis Suppurativa?: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with substantial psychosocial burden. Alexithymia, characterized by difficulties in identifying and expressing emotions, has been increas… What makes it notable here is that it approaches HS through pain, comorbidities, quality of life. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42569499 (https://pubmed.ncbi.nlm.nih.gov/42569499/))
- Evaluating the effectiveness of integrating a clinical pharmacist into a hidradenitis suppurativa clinic within the specialty of dermatology.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Ambulatory care pharmacists improve outcomes through medication management, adherence support, education and access to care. In dermatology, pharmacist integration is relatively new but may benefit patients with chron… What makes it notable here is that it approaches HS through quality of life, pain, wound care. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42539920 (https://pubmed.ncbi.nlm.nih.gov/42539920/))
- Surgical Outcomes of Hidradenitis Suppurativa Excision: Factors Impacting Wound Healing Time.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) can be treated surgically to excise recurrent and recalcitrant regions of disease activity. However, surgical outcomes are highly variable depending on closure method, concomitant medical… What makes it notable here is that it approaches HS through biologics, wound care, surgery. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42569806 (https://pubmed.ncbi.nlm.nih.gov/42569806/))
- Real-World Experience with Janus Kinase Inhibitors in Severe Refractory Hidradenitis Suppurativa: A Retrospective Case Series.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic inflammatory disease with limited treatment options for patients with severe, treatment-refractory disease. The JAK-STAT pathway represents a potential therapeutic target, al… What makes it notable here is that it approaches HS through pain, jak inhibitor. The main limitation to keep in mind is: As an observational analysis, it can describe associations but cannot securely prove cause and effect. (PMID 42591113 (https://pubmed.ncbi.nlm.nih.gov/42591113/))
- Successful treatment of hidradenitis suppurativa with vunakizumab: a case report and literature review.: The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic, recurrent, and disabling inflammatory skin disorder. To our knowledge, this study reports the first use of vunakizumab, a domestically developed anti-IL-17A monoclonal antib… What makes it notable here is that it approaches HS through pain, biologics. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. (PMID 42591326 (https://pubmed.ncbi.nlm.nih.gov/42591326/))

Featured publication

The featured paper is Does Alexithymia Affect Patients with Hidradenitis Suppurativa? in Clinical, cosmetic and investigational dermatology (PMID 42569499 (https://pubmed.ncbi.nlm.nih.gov/42569499/)). The abstract mainly says this: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with substantial psychosocial burden. Alexithymia, characterized by difficulties in identifying and expressing emotions, has been increas…

Why it stands out: it connects to the priority themes pain, comorbidities, quality of life and shows what HS researchers are trying to clarify right now. For readers, it matters because it gives one concrete example of how the field is framing a practical question or possible mechanism. The main limitation is that From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full.

What this may mean for patients (carefully, no advice)

If you live with HS, research updates can help you make sense of what’s being studied — for example which outcomes (pain, quality of life) researchers measure, or which comorbidities are increasingly part of the conversation.

But even when a study sounds promising, it usually does not tell you what is right for you personally. Consider using new findings as questions for your next appointment (e.g., “What are realistic goals for me?” or “Which related conditions should we keep an eye on?”), not as instructions.

What we don’t know / limitations

- This update includes only PubMed items with an abstract (without an abstract, safe summarization is limited).
- Studies vary widely (design, populations, outcome measures).
- This update provides no treatment advice and cannot assess individual risk.

Important: decisions belong in clinician conversations

This article is an editorial overview and is not medically reviewed. If something here worries or interests you, use it as a conversation starter for your next appointment. Decisions should always be made with qualified healthcare professionals.

FAQ

Why are there only a few new publications here?
This format is deliberately strict: it includes only new PubMed items from the monitoring window that have an abstract and were not already covered in earlier posts.

Does a new paper mean my treatment should change?
No. A single publication can be useful to know about, but it is usually not enough to guide decisions for one specific person.

Why emphasize limitations so much?
Because abstracts show only part of the picture. Study design, patient population, endpoints, and follow-up all matter before results can be interpreted responsibly.

Sources & original papers

Each point below maps to an original source (PubMed link, plus DOI/PMCID when available).

References

1. Reused skin grafts for treating hidradenitis suppurativa: A systematic review. - JPRAS open, 2026 — PMID 42565004 · DOI 10.1016/j.jpra.2026.06.005 · PMCID PMC13446193 - https://pubmed.ncbi.nlm.nih.gov/42565004/
2. Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. - Lancet (London, England), 2026 — PMID 42594914 · DOI 10.1016/S0140-6736(26)00896-2 - https://pubmed.ncbi.nlm.nih.gov/42594914/
3. A step forward in hidradenitis suppurativa consultations: The development of conversation cards. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42599869 · DOI 10.1111/jdv.70664 - https://pubmed.ncbi.nlm.nih.gov/42599869/
4. Body composition of hidradenitis suppurativa compared to psoriasis and healthy controls. - Clinical and experimental dermatology, 2026 — PMID 42596655 · DOI 10.1093/ced/llag365 - https://pubmed.ncbi.nlm.nih.gov/42596655/
5. Autoinflammatory Syndromes of Hidradenitis Suppurativa: Updates in Clinical Features, Emerging Associations, and Management. - Current rheumatology reports, 2026 — PMID 42593626 · DOI 10.1007/s11926-026-01232-0 - https://pubmed.ncbi.nlm.nih.gov/42593626/
6. The Metabolic Revolution in Dermatology: Obesity, Insulin Resistance, and Ultra-Processed Diets as Drivers of Skin Inflammation. - Journal of cutaneous medicine and surgery, 2026 — PMID 42590998 · DOI 10.1177/12034754261467034 - https://pubmed.ncbi.nlm.nih.gov/42590998/
7. Surgical Outcomes for Hidradenitis Suppurativa: Does Biologic Therapy Make a Difference? - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2026 — PMID 42585097 · DOI 10.1097/DSS.0000000000005305 - https://pubmed.ncbi.nlm.nih.gov/42585097/
8. Trained immunity in autoinflammatory diseases: Cellular reprogramming across the monogenic-polygenic spectrum. - European journal of cell biology, 2026 — PMID 42585948 · DOI 10.1016/j.ejcb.2026.151561 - https://pubmed.ncbi.nlm.nih.gov/42585948/
9. Clinical Settings and Patient Characteristics Associated with Outpatient Dermatology Care in Hidradenitis Suppurativa. - Dermatology (Basel, Switzerland), 2026 — PMID 42579642 · DOI 10.1159/drm/ackag004 - https://pubmed.ncbi.nlm.nih.gov/42579642/
10. Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of "Ozempic Face". - Dermatology and therapy, 2026 — PMID 42579223 · DOI 10.1007/s13555-026-01882-z - https://pubmed.ncbi.nlm.nih.gov/42579223/
11. Work impact of immune-mediated inflammatory skin diseases: A systematic review and meta-analysis. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42573445 · DOI 10.1111/jdv.70653 - https://pubmed.ncbi.nlm.nih.gov/42573445/
12. Glucagon-Like Peptide-1 Receptor Agonists and Related Incretin Therapies in Dermatology: Patient Selection and Shared Decision-Making. - Clinics in dermatology, 2026 — PMID 42571802 · DOI 10.1016/j.clindermatol.2026.08.005 - https://pubmed.ncbi.nlm.nih.gov/42571802/
13. The Ethical Role of Dermatologists in Smoking Cessation Counseling. - Clinics in dermatology, 2026 — PMID 42567212 · DOI 10.1016/j.clindermatol.2026.08.002 - https://pubmed.ncbi.nlm.nih.gov/42567212/
14. Real-World Experience with Janus Kinase Inhibitors in Severe Refractory Hidradenitis Suppurativa: A Retrospective Case Series. - Clinical, cosmetic and investigational dermatology, 2026 — PMID 42591113 · DOI 10.2147/CCID.S623786 · PMCID PMC13461383 - https://pubmed.ncbi.nlm.nih.gov/42591113/
15. Line-Field Confocal Optical Coherence Tomography Criteria of Hair Follicles in Patients with Hidradenitis Suppurativa versus Healthy Controls. - Dermatology (Basel, Switzerland), 2026 — PMID 42555536 · DOI 10.1159/000553220 · PMCID PMC13441261 - https://pubmed.ncbi.nlm.nih.gov/42555536/
16. Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa. - JAMA dermatology, 2026 — PMID 42555037 · DOI 10.1001/jamadermatol.2026.2633 · PMCID PMC13445090 - https://pubmed.ncbi.nlm.nih.gov/42555037/
17. [Cutaneous presentation of digestive tract disorders and liver disease]. - Dermatologie (Heidelberg, Germany), 2026 — PMID 42554803 · DOI 10.1007/s00105-026-05765-4 - https://pubmed.ncbi.nlm.nih.gov/42554803/
18. Originator versus biosimilar adalimumab in hidradenitis suppurativa: a real-world cohort study. - Expert opinion on biological therapy, 2026 — PMID 42552996 · DOI 10.1080/14712598.2026.2715455 - https://pubmed.ncbi.nlm.nih.gov/42552996/
19. Does Alexithymia Affect Patients with Hidradenitis Suppurativa? - Clinical, cosmetic and investigational dermatology, 2026 — PMID 42569499 · DOI 10.2147/CCID.S615526 · PMCID PMC13450608 - https://pubmed.ncbi.nlm.nih.gov/42569499/
20. Cutaneous Squamous Cell Carcinoma Arising From Hidradenitis Suppurativa and Epidermal Cyst: Clinical Characteristics, Baseline Neutrophil-To-Lymphocyte Ratio, and Disease-Specific Survival in a Retrospective Cohort. - The Journal of dermatology, 2026 — PMID 42543790 · DOI 10.1111/1346-8138.70433 - https://pubmed.ncbi.nlm.nih.gov/42543790/
21. Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial. - The Lancet regional health. Europe, 2026 — PMID 42577288 · DOI 10.1016/j.lanepe.2026.101721 · PMCID PMC13453948 - https://pubmed.ncbi.nlm.nih.gov/42577288/
22. Atypical facial hidradenitis suppurativa complicated by periorbital cellulitis: Case report and literature review. - SAGE open medical case reports, 2026 — PMID 42544137 · DOI 10.1177/2050313X261471655 · PMCID PMC13428835 - https://pubmed.ncbi.nlm.nih.gov/42544137/
23. Healthcare resource use, costs and health-related quality of life in the UK-Irish Atopic eczema Systemic Therapy Register (A-STAR): a pilot study. - Skin health and disease, 2026 — PMID 42540011 · DOI 10.1093/skinhd/vzag042 · PMCID PMC13425030 - https://pubmed.ncbi.nlm.nih.gov/42540011/
24. Serological biomarkers of extracellular matrix proteins are associated with hidradenitis suppurativa disease severity and treatment response. - Skin health and disease, 2026 — PMID 42539965 · DOI 10.1093/skinhd/vzag099 · PMCID PMC13424887 - https://pubmed.ncbi.nlm.nih.gov/42539965/
25. PubMed record 42539956 - Skin health and disease, 2026 — PMID 42539956 · DOI 10.1093/skinhd/vzag031 · PMCID PMC13424883 - https://pubmed.ncbi.nlm.nih.gov/42539956/
26. Socioeconomic factors and time to diagnosis in hidradenitis suppurativa. - Skin health and disease, 2026 — PMID 42539941 · DOI 10.1093/skinhd/vzag095 · PMCID PMC13424843 - https://pubmed.ncbi.nlm.nih.gov/42539941/
27. Evaluating the effectiveness of integrating a clinical pharmacist into a hidradenitis suppurativa clinic within the specialty of dermatology. - Skin health and disease, 2026 — PMID 42539920 · DOI 10.1093/skinhd/vzag049 · PMCID PMC13424882 - https://pubmed.ncbi.nlm.nih.gov/42539920/
28. Effectiveness and Safety of 40 mg Modified-Release Doxycycline for the Treatment of Hidradenitis Suppurativa: A Single-Center Retrospective Observational Study. - Dermatology and therapy, 2026 — PMID 42538508 · DOI 10.1007/s13555-026-01870-3 - https://pubmed.ncbi.nlm.nih.gov/42538508/
29. Successful treatment of hidradenitis suppurativa with vunakizumab: a case report and literature review. - Frontiers in immunology, 2026 — PMID 42591326 · DOI 10.3389/fimmu.2026.1852135 · PMCID PMC13461627 - https://pubmed.ncbi.nlm.nih.gov/42591326/
30. Severe Anemia in Hidradenitis Suppurativa Improved by Colostomy and Surgical Treatment: A Case Report. - Journal of plastic and reconstructive surgery, 2026 — PMID 42548980 · DOI 10.53045/jprs.2025-0044 · PMCID PMC13430234 - https://pubmed.ncbi.nlm.nih.gov/42548980/
31. PubMed record 42540167 - microPublication biology, 2026 — PMID 42540167 · DOI 10.17912/micropub.biology.002066 · PMCID PMC13425273 - https://pubmed.ncbi.nlm.nih.gov/42540167/
32. Surgical Outcomes of Hidradenitis Suppurativa Excision: Factors Impacting Wound Healing Time. - Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2026 — PMID 42569806 · DOI 10.1111/wrr.70190 · PMCID PMC13451998 - https://pubmed.ncbi.nlm.nih.gov/42569806/
33. Carbon Dioxide Laser Deroofing for Hidradenitis Suppurativa: Experience from an Asian Cohort. - Skin appendage disorders, 2026 — PMID 42565068 · DOI 10.1159/000553268 · PMCID PMC13446923 - https://pubmed.ncbi.nlm.nih.gov/42565068/
34. Risk Factors for Metabolic Syndrome in Patients with Hidradenitis Suppurativa. - Skin appendage disorders, 2026 — PMID 42541032 · DOI 10.1159/000553080 · PMCID PMC13427351 - https://pubmed.ncbi.nlm.nih.gov/42541032/
35. Association Between Hidradenitis Suppurativa and Polycystic Ovary Syndrome. - Cutis, 2026 — PMID 42594401 · DOI 10.12788/cutis.1403 - https://pubmed.ncbi.nlm.nih.gov/42594401/